Compare Abeona Therapeutics Inc (ABEO) vs EPR Properties (EPR) Price & Performance

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

EPR Properties trades at $60.32, down 0.13% recently, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 results, beating FFO estimates, and raised full-year guidance. Revenue grew to $699 million in 2026, though net income dipped to $263 million. Analysts maintain a consensus price target of $65.30, with 27% buy ratings, but technical indicators suggest near-term pressure.

The outlook is mixed: fundamental strength from dividend growth and acquisitions supports long-term value, but technical bearishness and elevated valuation ratios pose risks. Investors should weigh the 6% dividend yield against potential volatility from interest rate sensitivity and market sentiment shifts.